Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Xenotransplantation ; 12(3): 175-80, 2005 May.
Article in English | MEDLINE | ID: mdl-15807767

ABSTRACT

INTRODUCTION: Type 1 diabetes could possibly be treated by transplantation of pig pancreatic islets. In addition to medical difficulties and ethical problems, social hurdles may need to be overcome. We have evaluated the attitude of patients with type 1 diabetes to the xenotransplantation of pig pancreatic islets and to the potential risks associated with such treatment. METHODS: A survey of 214 patients with type 1 diabetes was carried out in France based on a multiple-choice questionnaire. RESULTS: At first, 52.0% of these patients indicated that they would agree to receive pig islet xenografts. The main sources of reluctance were the ''risk of disease transmission'' (55.5%) and ''risks not yet identified'' (48.7%). After they were told of the risk of cancer or infection associated with immunosuppression, 74.9% of the respondents chose to refuse the transplant, compared with 48.0% before they heard of such risks. A 68.1% would refuse the xenotransplant if it would not exempt them completely from being treated by insulin injections. Discontinuing insulin injections was the most important priority for diabetic patients (73.5%), rather than limitation of diabetes-related complications (52.5%) or increase in life expectancy (44.0%). After they were informed of all of the risks associated with the procedure, 70.5% of the respondents decided they would rather not take any risks, and said they would refuse pig islet transplantation. CONCLUSION: When diabetic patients learned about potential infectious risks and other risks associated with immunosuppression, reluctance to undergo xenotransplantation gained in significance or even led to refusal of the procedure.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Islets of Langerhans Transplantation , Swine , Transplantation, Heterologous , Treatment Refusal , Animals , Female , Humans , Islets of Langerhans Transplantation/adverse effects , Male , Middle Aged , Risk Assessment , Surveys and Questionnaires
2.
Xenotransplantation ; 12(2): 91-109, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15693840

ABSTRACT

The present historical review reports the clinical experiences of transplantations from animal to human. The first transplantation attempts were made without any knowledge of the species barrier. The pioneers of xenotransplantation realized xenotransfusions as early as the 16th century, then cell and tissue xenotransplantations in the 19th century. At the beginning of the 20th century, xenotransplantation of testicles became the latest craze. At the same time, and later in the 1960s, organ xenotransplantations were attempted, with disappointing results. Mathieu Jaboulay, Serge Voronoff, Keith Reemtsma, James Hardy, Denton Cooley, Thomas Starzl, Christiaan Barnard and Leonard Bailey were among the pionneers of xenotransplantation. Recent trials concerned above all tissue and cell xenotransplantations. Nowadays, with encapsulation, transgenesis, and cloning, great advances have been made for controlling xenograft rejection, but ethical questions linked to the risk of infections have become a major pre-occupation within the scientific community and the general population.


Subject(s)
Transplantation, Heterologous/history , Animals , Cell Transplantation/history , History, 16th Century , History, 19th Century , History, 20th Century , History, 21st Century , Humans , Immunosuppression Therapy/history , Organ Transplantation/history , Transplantation Chimera , Transplantation, Heterologous/ethics , Transplantation, Homologous/history
3.
Cell Transplant ; 11(7): 721-8, 2002.
Article in English | MEDLINE | ID: mdl-12518899

ABSTRACT

Encapsulation of islets of Langerhans confers protection against cell-mediated immune destruction and so should allow the transplantation of islets without immunosuppression. Xenotransplantation of encapsulated islets of Langerhans might therefore help overcome problems of human organ donor shortage. Given that islets exposed to sustained hyperglycemia show impaired beta-cell function, we set out to determine whether recipient treatment with insulin could improve transplantation success rate. Islets of Langerhans were obtained from Specific Germ-Free (SPF) pig pancreas and cultured overnight. Islets were encapsulated in AN69 fibers and implanted into the peritoneal cavity of diabetic mice. A group of implanted mice was treated with exogenous insulin from day 3 to day 7 after grafting. Islet implantation depressed plasma glucose in all the mice, both insulin treated and untreated. Glycemia slowly increased in the non-insulin-treated mice, whereas the decrease observed in the insulin-treated mice was maintained until day 29 of follow-up. We found significant differences between the two groups (p < 0.05 at day 18 and day 20, p < 0.001 at day 23 and day 29). No improvement of hyperglycemia was observed in diabetic mice implanted with empty fibers. When islet-containing fibers were removed from the peritoneal cavity of mice 1 month after the graft plasma glucose increased markedly. We demonstrate that treatment of recipients with exogenous insulin in the immediate posttransplantation period has a positive effect on beta-cell function in transplanted macroencapsulated porcine islets.


Subject(s)
Cell Death/drug effects , Diabetes Mellitus, Type 1/therapy , Graft Survival/drug effects , Hyperglycemia/drug therapy , Insulin/pharmacology , Islets of Langerhans Transplantation/methods , Islets of Langerhans/drug effects , Animals , Blood Glucose/drug effects , Blood Glucose/physiology , Cell Death/physiology , Cell Survival/drug effects , Cell Survival/immunology , Cells, Cultured , Disease Models, Animal , Graft Survival/immunology , Hyperglycemia/complications , Hyperglycemia/prevention & control , Insulin/immunology , Insulin/therapeutic use , Islets of Langerhans/cytology , Islets of Langerhans/immunology , Islets of Langerhans Transplantation/adverse effects , Islets of Langerhans Transplantation/immunology , Male , Mice , Pancreas, Artificial/adverse effects , Sus scrofa , Transplantation, Heterologous/adverse effects , Transplantation, Heterologous/immunology , Transplantation, Heterologous/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...